308 related articles for article (PubMed ID: 24496001)
41. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
42. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
Fili S; Karalaki M; Schaller B
Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
[TBL] [Abstract][Full Text] [Related]
43. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
44. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
45. RANKL inhibition in the treatment of bone metastases.
Lipton A; Jun S
Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Wang J; Chen TY; Qin S; Duan Y; Wang G
Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
[TBL] [Abstract][Full Text] [Related]
47. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL
J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
49. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
51. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
52. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
53. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Furugaki K; Moriya Y; Iwai T; Yorozu K; Yanagisawa M; Kondoh K; Fujimoto-Ohuchi K; Mori K
Clin Exp Metastasis; 2011 Oct; 28(7):649-59. PubMed ID: 21688034
[TBL] [Abstract][Full Text] [Related]
54. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.
Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL
Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
56. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
57. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
58. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.
Kim HK; Morgan-Bagley S; Kostenuik P
J Bone Miner Res; 2006 Dec; 21(12):1946-54. PubMed ID: 17002576
[TBL] [Abstract][Full Text] [Related]
59. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
60. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
